Applying Quantitative Immunology To The Analysis Of Complex Genetic Diseases
Funder
National Health and Medical Research Council
Funding Amount
$864,596.00
Summary
The immune response of each individual varies. For some, the response invoked by foreign challenge is weak, leading to a lifetime of difficulty with infection. For others, the response is stronger, yielding excellent immunity, but opening the potential for overactive responses to self-material and autoimmune disease. We have a new theory for how the health of our immune system can be measured and we aim to apply it to understand the genesis of the many different forms of human immune diseases.
Pharmacogenomics And Mechanistic Basis Of Drug Hypersensitivity
Funder
National Health and Medical Research Council
Funding Amount
$677,220.00
Summary
Drug allergy causes physical harm, anxiety and may limit treatment options. We introduced personalised genetic testing to prevent one such drug hypersensitivity. Genetic information from patients who have had adverse drug reactions will be used to work out how drugs trigger severe allergic reactions and develop strategies to predict these reactions and design safer drugs. This research has relevance to our understanding of other inflammatory disease such as autoimmune disease and multiple sclero ....Drug allergy causes physical harm, anxiety and may limit treatment options. We introduced personalised genetic testing to prevent one such drug hypersensitivity. Genetic information from patients who have had adverse drug reactions will be used to work out how drugs trigger severe allergic reactions and develop strategies to predict these reactions and design safer drugs. This research has relevance to our understanding of other inflammatory disease such as autoimmune disease and multiple sclerosis.Read moreRead less
Characterisation Of T-cell Responses In Drug Hypersensitivity
Funder
National Health and Medical Research Council
Funding Amount
$306,338.00
Summary
Drug hypersensitivity reactions (DIHS) are a catastrophic form of adverse drug reaction. This study will use the drug abacavir, a cause of drug hypersensitivity to examine the way certain immune cells react and determine whether responses to viruses that are persistent in our bodies play a role these development of these reactions. This will help inform the immunological basis of DIHS as well as new treatments and potential ways of identifying drugs likely to cause these reactions in the pre-mar ....Drug hypersensitivity reactions (DIHS) are a catastrophic form of adverse drug reaction. This study will use the drug abacavir, a cause of drug hypersensitivity to examine the way certain immune cells react and determine whether responses to viruses that are persistent in our bodies play a role these development of these reactions. This will help inform the immunological basis of DIHS as well as new treatments and potential ways of identifying drugs likely to cause these reactions in the pre-marketing phase of drug development.Read moreRead less
Rogue B Cell Clones In Patients With Autoimmune Disease
Funder
National Health and Medical Research Council
Funding Amount
$916,670.00
Summary
Our immune system protects us from disease by producing antibodies. However, 5% of Australians suffer from an autoimmune disease where they produce “auto” antibodies, which attack their own organs. This research will study the cells (termed B cells) responsible for making autoantibodies to determine how they differ from B cells that defend against disease. The goal is to develop therapies that eliminate autoantibody producing B cells from patients while preserving the immune system.
Immunoglobulin Germline Genes, BCR Repertoire Development And Disease Susceptibility. An Investigation Of Haplotypic Variation Between Individuals
Funder
National Health and Medical Research Council
Funding Amount
$519,828.00
Summary
The immune system is capable of making a repertoire of protective antibodies including literally tens of millions of different specificities. These are produced by permutations and combinations of a small set of ‘germline’ genes. This project will analyse how individual variations in the germline genes lead to individual differences in the repertoires of available antibodies, and will investigate whether or not such differences contribute to our susceptibility to infection and autoimmune disease ....The immune system is capable of making a repertoire of protective antibodies including literally tens of millions of different specificities. These are produced by permutations and combinations of a small set of ‘germline’ genes. This project will analyse how individual variations in the germline genes lead to individual differences in the repertoires of available antibodies, and will investigate whether or not such differences contribute to our susceptibility to infection and autoimmune diseases.Read moreRead less
How Do The Vitamin D Receptor Activation Genes CYP27B1 And CYP24A1 Alter Susceptibility To Autoimmune Diseases?
Funder
National Health and Medical Research Council
Funding Amount
$508,518.00
Summary
Because Vitamin D deficiency has long been associated with autoimmune diseases, clinical trials with various forms of Vitamin D have been conducted and are underway. Yet the basis for the Vitamin D association has not been established. In 2012, two vitamin D genes were shown to alter susceptibility to autoimmune diseases. The goal of this project is to determine how these genes influence immune tolerance mechanisms, and so develop novel and improved therapeutic approaches based on Vitamin D.
The Influence Of HIV On T Cell Function And Application To Vaccine Design.
Funder
National Health and Medical Research Council
Funding Amount
$427,899.00
Summary
Development of a safe, effective vaccine remains the only viable means of abating the human immunodeficiency virus (HIV) pandemic in the long term. Scientists must develop a vaccine that could protect against many diverse HIV strains worldwide. This research aims to understand the ways in which HIV mutates to avoid human immune responses in order to determine how best to design a vaccine. The findings could be applied to other infectious diseases for which vaccines are also needed.
Investigation Into Host Susceptibility And Immune Responses In Young Children With Acute Wheezing Due To Human Rhinovirus Group C Infection
Funder
National Health and Medical Research Council
Funding Amount
$682,711.00
Summary
We recently made the surprising discovery that a new viral group, human rhinovirus group C (HRV-C), causes the majority of acute asthma in children. We also found that it causes half of the acute wheezing attacks in younger children, and is the only respiratory virus associated with allergy. So, HRV-C may be the key to the relationship between allergy and asthma. The planned project will focus on whether young children who wheeze with HRV-C have related defects in their immune system.
The Role Of Long Peptide Epitopes In Antiviral CD8+ T Cell Recognition.
Funder
National Health and Medical Research Council
Funding Amount
$434,652.00
Summary
The immune response to viral infection involves killer T cell recognition of small viral peptides presented by infected cells. Researchers have been attempting to identify the viral peptides that are recognised by T cells. Although these studies have been successful, the major aim of this project is to investigate if the role of unusually long peptides has been underestimated. This project should lead to enhanced monitoring of immune responses and improvements in vaccine design.
Determining The Biological Significance Of Allelic Sequence Variation Within The T Cell Receptor Loci
Funder
National Health and Medical Research Council
Funding Amount
$627,549.00
Summary
T lymphocytes play a pivotal role in the immune system by recognising virus-infected tissue through the use of highly specific T cell receptors (TCRs). This project will investigate the importance of genetic variation in the TCR genes in influencing how we fight infections. Advances in these areas will assist in understanding susceptibility to some autoimmune diseases as well as aiding in the development of new "intelligent" vaccines and individualised therapeutics.